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Background:  Clinical  signs  and  symptoms  of  different  airway  pathogens  are  generally  indistinguish-
able,  making  laboratory  tests  essential  for  clinical  decisions  regarding  isolation  and  antiviral  therapy.
Immunochromatographic  tests  (ICT)  and direct  immunoﬂuorescence  assays  (DFA)  have  lower  sensitiv-
ities and  speciﬁcities  than  molecular  assays,  but  have  the  advantage  of quick  turnaround  times  and
ease-of-use.
Objective:  To  evaluate  the performance  of a rapid  molecular  assay,  ARIES  FluA/B  &  RSV, using  laboratory
developed  RT-PCR  assays  (LDA),  ICT  (BinaxNOW)  and  DFA.
Methods:  Analytical  and  clinical  performance  were  evaluated  in a retrospective  study  arm (stored  res-
piratory  samples  obtained  between  2006–2015)  and  a prospective  study  arm  (unselected  fresh  clinical
samples  obtained  between  December  2015  and  March  2016  tested  in  parallel  with  LDAs).
Results:  Genotype  inclusivity  and  analytical  speciﬁcity  was  100%.  However,  ARIES  was  0.5  log, 1–2logs  and
2.5logs  less  sensitive  for ﬂuA, RSV  and  ﬂuB respectively,  compared  to LDA.  In total,  447  clinical  samples
were  included,  of  which  15.4%  tested  positive  for  ﬂuA,  9.2%  for ﬂuB  and  26.0%  for  RSV,  in both  LDA and
ARIES.  ARIES  clinical  sensitivity  compared  to LDA  was  98.6%  (ﬂuA),  93.3%  (ﬂuB)  and  95.1% (RSV).  Clinical
speciﬁcity  was  100%  for all targets.  ARIES  detected  10.6%  (4 ﬂuA,  8 ﬂuB,  11  RSV)  and  26.9%  (7 ﬂuA, 3  ﬂuB,
22  RSV)  more  samples  compared  to DFA  and  ICT,  all conﬁrmed  by LDA.
Conclusion:  Although  analytically  ARIES  is less  sensitive  than  LDA,  the  clinical  performance  of  the  assay
in  our  tertiary  care  setting  was comparable,  and  signiﬁcantly  better  than  that  of  the  established  rapid
assays.
ublis© 2016  The  Authors.  P
. Background
Rapid and accurate detection of inﬂuenza A (ﬂuA) and B (ﬂuB)
iruses and respiratory syncytial virus (RSV) is important for clin-
cal patient management and infection control purposes. Rapid
aboratory diagnostics may  result in less antibiotic prescription and
ore frequent use of antivirals [1–3]. Molecular assays are consid-
red to be the standard for the detection of respiratory viruses,
ut may  be relatively time consuming and need qualiﬁed molecu-
ar laboratory personnel to execute and for result interpretation.
urrently available rapid tests, like direct immunoﬂuorescence
∗ Corresponding author at: Erasmus Medical Centre, Department of Viroscience,
oom Na1017, Wytemanweg 80, 3015 CE Rotterdam,The Netherlands.
E-mail address: s.pas@erasmusmc.nl (S.D. Pas).
ttp://dx.doi.org/10.1016/j.jcv.2016.10.019
386-6532/© 2016 The Authors. Published by Elsevier B.V. This is an open access article uhed  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
assays (DFA) or immunochromatographic tests (ICT) have quick
turnaround times, but are less sensitive and less speciﬁc compared
to molecular assays.
2. Objective
The aim of the study was  to evaluate the performance of the
ARIES FluA/B and RSV assay by comparing it to routine molecular
laboratory developed assays (LDA), rapid DFA and rapid ICT.
3. Study design3.1. ARIES inﬂuenza A, B and RSV assay
The ARIES system (Luminex) is a FDA and CE/IVD marked
molecular diagnostic, sample-to-answer system, based on a
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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robe-less RT-PCR using isoguanine and 5-methylisocytosine
aseparing (MultiCode) and melt curve analysis for detection [4,5].
00 l respiratory sample is pipetted directly into an ARIES cas-
ette, and placed in one of the two independent modules, which can
un 1–6 cassettes each, with a sample-to-result time of 2 h (includ-
ng a hands-on–time of about 5–10 min  per 12 samples). The ARIES
ystem runs a nucleic acid extraction, multiplex MultiCode RT-PCR
nd melting curve analysis, detecting ﬂuA, ﬂuB, RSV and a speci-
en  process control (SPC) in one cassette. Results were generated
sing assay protocol version A (Luminex).
.2. Analytical performance evaluation
Genotype inclusivity was assessed using a reference panel,
ncluding 16 avian (H1-H16) and 33 human ﬂuA strains (H1N1,
1N1p2009, H3N2, H5N1, H7N7, H2N2), reﬂecting viruses circu-
ating between 1968 and 2014, 3 ﬂuB strains (2 Yamagata and
 Victoria) and 2 RSV (A/B) strains. Avian and highly pathogenic
uA strains were inactivated using MagNaPureLC lysisbuffer (200ul
ample + 300ul lysisbuffer) (Roche, Almere, the Netherlands) before
unning in the ARIES. Analytical speciﬁcity was assessed using high
itred virusstocks (median Ct-value 17, range ∼11–26) including
hinovirus, enterovirus, parecho 1–3, HMPV, parainﬂuenza 1–4,
CoV-229e, −OC43,-NL63, adenovirus, bocavirus, rubella, measles,
umps, rotavirus, sapovirus, astrovirus, hepatitis B, E and D viruses,
oro-1 and 2, HSV1 and 2, CMV, EBV, VZV, HHV6, HHV7, HHV8, B19,
PV, rhCMV, JC and BK viruses and Mycoplasma pneumoniae.
Analytical sensitivity and linearity were deter-
ined using half log dilution series of cell
ulture isolate ﬂuA/H1N1/Netherlands/202/95,
uB/Yamagata/Netherlands/022/95, RSVA and RSVB, until neg-
tive. Repeatability was assessed using replicates of a process
ontrol, positive for ﬂuA, ﬂuB and RSV. Results were compared
o an ISO15189:2012 validated laboratory developed automated
eal-time RT-PCR assays using Aurora FLOW (Roche, Almere, the
etherlands) (LDA) (Supplementary materials).
.3. Clinical performance evaluation
Clinical performance was evaluated both retrospectively, for
nclusion of known positive ﬂuA/B/RSV samples, and prospectively
or inclusion of fresh respiratory tracts samples and head-to-head
omparison with the routinely used LDA.
For retrospective evaluation stored (−80 ◦C) pre-treated respi-
atory tract samples from January 2006–July 2015 were selected;
rom each year 4 positive samples per species (ﬂuA, ﬂuB, RSVA and
SVB) to include genotypic variances and different sample types.
rospective evaluation was performed on unselected fresh respira-
ory tract samples from patients presented to our hospital between
ecember 2015–March 2016.
For retrospective evaluation, ARIES results were compared
o historical LDA, DFA and ICT results retrieved from the LIMS
atabase. The historical LDA results were obtained using primers
nd probes identical to those described above; sample pre-
reatment, isolation and real-time PCR however, were performed
s previously described [6] (Supplementary methods).
Both retrospective and prospective discrepant samples were
onﬁrmed by repeating both ARIES and LDA by using Aurora FLOW,
s described above. Results after discrepancy testing were used for
urther analysis.DFA was performed as previously described [7] and ICT was
erformed using BinaxNOW® Inﬂuenza A and B and BinaxNOW®
SV (Alere health, Tilburg The Netherlands) as described by the
anufacturer.ical Virology 85 (2016) 65–70
This study was  approved by the Medical Ethical Committee of
the Erasmus MC  (MEC-2015-475).
3.4. Statistical analysis
Statistical analysis was  performed using IBM SPSS v21 (Table 2)
and Deming regression and Mann-Whitney test for non-parametric
non paired data was performed using GraphPad Prism v5.00 for
Windows. 95% Conﬁdence intervals were calculated using the Wil-
son method, Epitools (http://epitools.ausvet.com.au).
4. Results
4.1. Analytical performance of ARIES
To determine whether external lysis could be used in the ARIES
system, 6 human inﬂuenza A virus strains were tested with and
without external lysis, resulting in comparable Ct-values (median
Ct = 1.1, range 0.6–2.2), taking dilution factor into account. All
54 avian and human ﬂuA, ﬂuB, RSVA and RSVB strains tested for
genotype inclusivity were detected by the ARIES. No false positive
reactions with non-ﬂuA/ﬂuB/RSV virusstocks were detected.
Analytical sensitivity testing showed comparable results to LDA
(≤0.5 log) for ﬂuA, but 1 log, 2 logs and 2.5 logs less sensitive for
RSVA, RSVB and ﬂuB, respectively. To determine the repeatability,
%CV was calculated of 37 replicates of a positive process control
(PPC) containing each ﬂuA, ﬂuB and RSVA/B viruses, resulting in
a%CV of 2.7–3.6%. The concentration of ﬂuB (LDA Ct-value 26.4) in
the PPC was  close to the ARIES limit of detection and tested positive
32 out of 37 (86.5%), ﬂuA (LDA Ct-value 27.5) and RSV (LDA Ct-value
RSVA 25.1, RSVB 26.4) tested positive in all replicates. T- and F-test
showed no signiﬁcant difference (<0.05) of the data retrieved in
three subsequent months, implying PPC can be tested only once a
month.
4.2. Clinical performance of ARIES
In total 447 clinical respiratory tract samples were included, of
which 162 belonged to the retrospective study arm, speciﬁcally 133
nasal washings, 14 throat swabs, 6 bronchial alveolar lavages (BAL),
9 sputa and 1 nose swab, of which 23.5% were positive for ﬂuA (9.9%
H1N1p09, 1.2% H1N1, 11.7% H3N2 and 0.6% H1N1 + H3N2) 19.8% for
ﬂuB (8.6% Victoria, 10.5% Yamagata,1 sample (0.6%) non-typeable)
and 50.6% for RSV (26.5% RSVA and 24.1% RSVB). Additionally, 285
prospective samples were included (55 nasal washings), 170 throat
swabs, 41 BAL, 15 sputa, 2 nose swabs, 1 mouth swab and 1 pleural
ﬂuid of which 10.8% was  positive for ﬂuA (all H1N1p09 strains),
3.5% for ﬂuB (all Victoria strains) and 11.9% for RSV (5.6% RSVA and
6.3% RSVB).
The 447 clinical samples were collected from 406 patients
(Table 1). In total for both study arms 15.4%, 9.2% and 26% of the
samples were positive for ﬂuA, ﬂuB and RSV (13.2% RSVA and
12.8% RSVB), respectively for both LDA and ARIES. Conﬁrmed dis-
crepant results were found in 10 samples: 1 ﬂuA (LDA Ct-value
36.0, H1N1p09 strain), 3 ﬂuB (LDA Ct-values 32.5–33.9, all Victoria
strains) and 6 RSVA (LDA Ct-values 29.3–34.5). In 6 (all nasal wash-
ings) of these 10 discrepant samples two viruses were detected
using LDA (Table 1), having a common result in ARIES: the viral
RNA with the highest concentration (LDA Ct-values 15.8–23.7) was
detected, the viral RNA with the lowest concentration (LDA Ct-
values 31.5–34.5) was  not detected. LDA was also not conﬁrmed
by DFA or ICT for these samples, although 1 nasal washing (RSVA
LDA Ct-value 29.3) was  propagated by virus culture. One positive
LDA result (throat swab, ﬂuA LDA Ct-value 36.0) was  conﬁrmed
by a sample from the same patient, drawn earlier in the infection,
which tested positive in both ARIES and LDA.
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Table  1
Characteristics of clinical samples.
Characteristics Total LDA FluA+ LDA FluB+ LDA RSV+
n % of all n % of all n % of all n % of all
Sample type
nose wash 189 42.3% 34 7.6% 27 6.0% 94 21.0%
throat  swab in UTM 183 40.9% 26 5.8% 11 2.5% 22 4.9%
BAL  48 10.7% 3 0.7% 2 0.4% 3 0.7%
sputum 22 4.9% 4 0.9% 4 0.9% 3 0.7%
nose  swab 3 0.7% 2 0.4% 1 0.2% 0 0.0%
pleural ﬂuid 1 0.2% 1 0.2% 0 0.0% 0 0.0%
mouth swab 1 0.2% 0 0.0% 0 0.0% 0 0.0%
Sex
Male 242 54.1% 47 10.5% 24 5.4% 68 15.2%
Female 205 45.9% 23 5.1% 21 4.7% 54 12.1%
Age
0–1  years 106 23.7% 11 2.5% 0 0.0% 77 17.2%
1–5  years 46 10.3% 13 2.9% 9 2.0% 12 2.7%
5–18  years 61 13.6% 14 3.1% 18 4.0% 7 1.6%
18–65  years 175 39.1% 25 5.6% 16 3.6% 23 5.1%
65+  years 59 13.2% 7 1.6% 2 0.4% 3 0.7%
Species genotype
A H1N1pdm09 46 10.3% 46 10.3%
A  H1seasonal 2 0.4% 2 0.4%
A  H3N2 18 4.0% 18 4.0%
A  H3N2 + H1N1seasonal 1 0.2% 1 0.2%
B  Victoria 22 4.9% 22 4.9%
B Yamagata 17 3.8% 17 3.8%
B  unknown 1 0.2% 1 0.2%
RSV  A 59 13.2% 59 13.2%
RSV  B 57 12.8% 57 12.8%
RSV  A + B 1 0.2% 1 0.2%
A H1N1pdm09 + B Victoria 2 0.4% 2 0.4% 2 0.4%
A  H3N2 + RSV A 1 0.2% 1 0.2% 1 0.2%
.4% 
.2% 
8.5%
r
d
i
p
w
1
B
A
L
B
y
t
m
M
o
m
A
T
C
*B  Victoria + RSV A 2 0
B  Yamagata + RSV A 1 0
negative 217 4
Clinical sensitivity and speciﬁcity were assessed using both
etrospective and prospective samples with LDA as the golden stan-
ard and compared to DFA and ICT (Table 2, Fig. 1). This resulted
n a superior clinical sensitivity for ARIES ﬂuA, ﬂuB and RSV com-
ared to the other two rapid tests, DFA and ICT. Clinical speciﬁcity
as quite equal for ARIES, DFA and ICT, ranging from 95.5% up to
00% in the present study. Six ARIES positive samples (3 ﬂuA (2x
AL, 1 sputum), 1 ﬂuB (nasal washing) and 2 RSV (throat swabs),
RIES Ct-values 38.1- 40.1) could initially not be conﬁrmed by
DA, but after sample pre-treatment for sputum, nasal washing and
ALs(10x dilution) and subsequent retesting in both ARIES and LDA
ielded equivalent negative results. To gain insight and to analyze
he difference in Ct-value of the LDA positive samples, which were
issed in the rapid tests (ARIES, ICT and DFA) Fig. 1 was plotted.
ann-Whitney test showed a statistical difference in LDA Ct-values
f ARIES missed samples compared to ICT and DFA in all cases,
eaning that both ICT and DFA are signiﬁcantly less sensitive than
RIES. Compared to DFA (n = 217) and ICT (n = 117), ARIES detected
able 2
linical sensitivity and speciﬁcity of inﬂuenza A, B and RSV for ARIES, ICT and DFA using L
Sensitivity 
Virus Assay N % [95%CI] 
Inﬂuenza A ARIES 447 98.6 [92.3–99.8]
DFA  217 88.2 [73.4–95.3]
ICT  (Binax) 116 74.1 [55.3–86.8]
Inﬂuenza B ARIES 447 93.3 [82.1–97.7]
DFA  216 63.0 [44.2–78.5]
ICT  (Binax) 116 37.5 [13.7–69.4]
RSV  ARIES 447 95.1 [89.7–97.7]
DFA  217 84.9 [76.3–90.8]
ICT  (Binax) 117 70.2 [59.8–79.0]
First round testing (before discrepancy analysis) showed a speciﬁcity of 99.2% for ﬂuA, 92 0.4% 2 0.4%
1 0.2% 1 0.2%
in 23 (10.6%; 4 ﬂuA, 8 ﬂuB, 11 RSV) and 33 (28.2%; 7 ﬂuA, 4 ﬂuB,
22 RSV) more samples viral RNA respectively, all conﬁrmed by LDA
(Ct-value range 16.5–31.6) (Fig. 1).
Fig. 2 shows the distribution of paired LDA and ARIES Ct-values,
using LDA as golden standard. Positive LDA samples only were
taken into account. Deming regression analysis of all targets shows
a good correlation between the two methods, although ARIES had
an average Ct-delay of 5.2 ± 1.6 for ﬂuA, 10.8 ± 1.7 for ﬂuB and
6.1 ± 1.9 for RSV, which was conﬁrmed in the analytical perfor-
mance evaluation (data not shown).
To assess robustness of the ARIES, a failed cassette analyses
was performed. In total 669 cassettes were run, 180 pre-‘research
use only’ (RUO) and 489 optimised RUO cassettes, of which 2.44%
(pre-RUO) and 1.95% (RUO, FDA approved in June 2016) failed
respectively. Of the 286 prospective fresh samples 10 cassettes
failed: 3 nasal washings, 4x BAL and one sputum were viscous.
Of these samples, 150 l was diluted in 900 l DMEM containing
40% FBS, vortexed and centrifuged. 200 l of the supernatant was
DA as golden standard.
Speciﬁcity
N % [95%CI] N
 69/70 100.0*[99.0–100.0] 377/377
 30/34 99.5 [97.0–99.9] 182/183
 20/27 95.5 [97.0.–99.9] 85/89
 42/45 100.0*[99.1–100.0] 402/402
 17/27 100.0 [98.0–100.0] 189/189
 3/8 99.1 [94.9–99.8] 107/108
 116/122 100.0*[98.8–100.0] 323/325
 79/93 100.0 [97.0–100.0] 124/124
 59/84 100.0 [89.6–100.0] 33/33
9.4% for RSV and 99.8% for ﬂuB.
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Fig. 1. Comparison of ARIES, ICT and DFA inﬂuenza A virus (A), inﬂuenza B virus (B) and RSV (C) positive and negative samples using LDA Ct-values as golden standard.
LDA  Ct-value ≥45 was  considered negative. Mann-Whitney test for non-parametric non-paired data showed signiﬁcant differences in LDA Ct-values for ﬂuA, ﬂuB and RSV
between ARIES negative sample group and ICT or DFA negative samples, indicating a higher sensitivity of ARIES.
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Fig. 2. Correlation plot of paired LDA and ARIES Ct-values of LDA positive ﬂuA (A), ﬂuB (B) or RSVA/B (C) samples. Deming regression (red line, in case of RSV: plotted for
total  RSV data) of the data showing a signiﬁcant deviation from zero for all viruses, slope and Y-axis intercept is shown in the ﬁgure. X = Y line is plotted for reference (dotted
grey  line).
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uccessfully retested in ARIES. Furthermore, one pre-treated nasal
ashing and one untreated throat swab failed.
. Conclusions
In this study we evaluated the performance of the ARIES Flu
/B and RSV assay, a molecular diagnostic rapid test and com-
ared it to LDA and two established, non-molecular rapid assays.
he analytical performance, containing genotype inclusivity, speci-
city, linearity and repeatability showed comparable results to the
DA assays. The analytical sensitivity of ﬂuA is also comparable to
hat of the LDA, though the ﬂuB and RSV assays were up to 2.5 logs
ess sensitive.
However, though probe-less real-time PCRs are generally
onsidered as less speciﬁc, the increased specify due to the
soguanine/5-methylisocytosine chemistry used in ARIES results in
 clinical sensitivity which exceeds that of ICT and DFA, and is com-
arable to that of the LDA in the present study. ARIES was  not able
o detect 10 samples (2.2%) containing high LDA Ct-values (LDA
t-value 28.8–36.0). Though, these Ct-values are expected to be
ndetectable in the ARIES as interpolated from the detectable range
easured in the analytical sensitivity experiment (data not shown).
hereas the number of samples, which could not be detected by
FA and ICT was much higher and contained signiﬁcantly lower
t-values (Fig. 1). 6 of the 10 samples missed by the ARIES sys-
em were double infections; in all 6 cases ARIES only detected the
iruses with the lower LDA Ct-value (Table 1).
The ARIES ﬂuA/B/RSV assay was ofﬁcially FDA-approved for
asopharyngeal swabs. However, the most common respiratory
ract sample types in our routine diagnostic setting are throat swabs
n universal transport medium (adults) and nasal washings (chil-
ren). Hence, these latter sample types and sputa and BALs were
ncluded in this study. Nasal washings, BAL and sputa were pre-
reated as part of routine work-up for the retrospective study arm
rior to testing on the ARIES system, resulting in these cases in suc-
essful runs. In the prospective study on the contrary, these sample
ypes were tested untreated and 10 of 285 cassettes failed, probably
ue to viscosity of the samples as the internal specimen control was
ither negative or out of range. One may  argue if viscosity/human
ells of these fresh (untreated) samples may  have been the cause
or 6 samples (1.3%) of the prospective study arm to initially test
false) positive without LDA or DFA conﬁrmation. These samples
ere either ﬂuA (n = 3), ﬂuB (n = 1) or RSV (n = 2) positive by ARIES
nly and had high ARIES Ct-values ranging from 38.1 to 40.1. On
he other hand, 26 (11.5%) of the LDA conﬁrmed ARIES (true) posi-
ive samples also had ARIES Ct-values of >38. If we  compared these
t-values to those of the LDA assays, the range varied between
DA Ct-value 25.7–34.8 for RSV, Ct-value 24.7–29.7 for ﬂuB and
t-value 30.4-32.3 for ﬂuA. Therefore, high ARIES Ct-values should
e considered as positive.
All LDA assays are routinely performed on pre-treated samples
6]. During this pre-treatment cells are removed from the fresh
ample and the supernatant is diluted ∼10 times. Since the ARIES
nalytical sensitivity for ﬂuA is comparable to LDA, it is possible that
he 3 ARIES+/LDA- ﬂuA samples were missed by the LDA due to pre-
reatment. This scenario is less likely for the 7 RSV or ﬂuB, since the
RIES analytical sensitivity was 1–2.5 log less sensitive than LDA.
ndeed, ARIES false positivity cannot be ruled out in these cases.
ll failed cassettes and “false-positive” non-throat swab samples
ere pre-treated and repeated in both ARIES and LDA. No failing
assettes or false positivity was observed hereafter. Throat swabs
ere repeated untreated in both assays and positivity could not be
onﬁrmed. Therefore, we recommend to dilute viscous nasal wash-
ngs, sputa and BAL sample types prior to running on the ARIES
ystem, so failure of cassettes by inhibition as well as possible falseical Virology 85 (2016) 65–70 69
positivity can be avoided, which may  positively affect the speciﬁcity
of the ARIES.
The BinaxNow inﬂuenza and RSV (ICT) assays are commonly
used and many clinical studies have addressed sensitivity and
speciﬁcity before, showing a lot of variation. [8–20] The pub-
lished sensitivity varied between a modest 59%–83% for inﬂuenza
A virus, 72%–90% for RSV and a poor sensitivity for inﬂuenza B
virus (33%–69%). The ICT sensitivity observed in our study conﬁrms
these ﬁndings. Others suggest to conﬁrm ICT or DFA rapid tests with
techniques like RT-PCR or virus culture to conduct proper results
[8,10,11,14,15,20], due to low sensitivities. We suggest that conﬁr-
matory testing for ﬂuA, ﬂuB or RSV may  no longer be needed when
using ARIES, because of the superior sensitivity to antigen rapid
tests. Testing for other viral or bacterial respiratory pathogens may
be of higher clinical importance.
In terms of ease-of-use, is ARIES equal to systems like GeneXprt
(Cepheid) or other molecular rapid test platforms, however most
platforms have runtimes of < 1 h, where ARIES’ runtimes are up to
2 h. Nevertheless, other platforms do not have the possibility to run
in-house developed real-time assays, which generic ARIES cassettes
do allow the user to develop.
In conclusion, the ARIES assay is a rapid molecular based assay
for detection of inﬂuenza A virus, inﬂuenza B virus and RSV. The
platform showed a high clinical speciﬁcity and sensitivity, which is
comparable to LDA and better than those of established rapid assays
such as DFA and ICT. Other respiratory tract samples than throat
swabs can be run on the ARIES, but pre-dilution is recommended
to gain more reliable results.
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